Allogeneic immune replacement as cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 3, Issue 7, 2003, Pages 1051-1060

  Chakrabarti, Sakti ^a   Childs, Richard ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Allogeneic haematopoietic transplantation; Graft versus leukaemia (GVL); Graft versus tumour (GVT); Haematological malignancy; Immunotherapy; Metastatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; FLUDARABINE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG TOXICITY; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; REVIEW; STEM CELL MOBILIZATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0142087563     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.7.1051     Document Type: Review

References (69)

1. DE BUEGER M, BAKKER A, VAN ROOD JJ, VAN DER WOUDE F, GOULMY E: Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. (1992) 149:1788-1794.
2. GOULMY E: Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. (1997) 157:125-140.
3. WARREN EH, GREENBERG PD, RIDDELL SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood (1998) 91:2197-2207.
4. BURCHENAL JH, OETTGEN HF: Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res. (1960) 20:425.
5. BARNES D, LOUTIT J: Treatment of murine leukaemia with X-rays and homologous bone marrow: II. Br. J. Haematol. (1957) 3:241-252.
6. MATHE G, AMIEL JL, SCHWARZENBERG L, CATTAN A, SCHNEIDER M: Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. (1965) 25:1525-1531.
7. WEIDEN PL, FLOURNOY N, THOMAS ED et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. (1979) 300:1068-1073.
8. WEIDEN PL, SULLIVAN KM, FLOURNOY N, STORB R, THOMAS ED: Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. (1981) 304:1529-1533.
9. HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 75:555-562.
10. ANTIN JH: Graft-versus-leukemia: no longer an epiphenomenon. Blood (1993) 82:2273-2277.
11. CULLIS JO, JIANG YZ, SCHWARER AP, HUGHES TP, BARRETT AJ, GOLDMAN JM: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood (1992) 79:1379-1381.
12. DROBYSKI WR, KEEVER CA, ROTH MS et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood (1993) 82:2310-2318.
13. KOLB HJ, SCHATTENBERG A, GOLDMAN JM et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood (1995) 86:2041-2050.
14. VAN RHEE F, LIN F, CULLIS JO et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood (1994) 83:3377-3383.
15. FABER LM, LUXEMBURG-HEIJS SA, WILLEMZE R, FALKENBURG JH: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J. Exp. Med. (1992) 176:1283-1289.
16. JIANG YZ, BARRETT AJ: Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp. Hematol. (1995) 23:1167-1172.
17. JIANG YZ, MAVROUDIS D, DERMIME S et al.: Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br. J. Haematol. (1996) 93:606-612.
18. GAMBACORTI-PASSERINI C, BERTAZZOLI C, DERMIME S, SCARDINO A, SCHENDEL D, PARMIANI G: Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Clin. Cancer Res. (1997) 3:675-683.
19. OHMINAMI H, YASUKAWA M, FUJITA S: HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood (2000) 95:286-293.
20. OKA Y, ELISSEEVA OA, TSUBOI A et al.: Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics (2000) 51:99-107.
21. RUGGERI L, CAPANNI M, CASUCCI M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 94:333-339.
22. CHILDS R, CLAVE E, CONTENTIN N et al.: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 94:3234-3241.
23. SLAVIN S, NAGLER A, NAPARSTEK E et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood (1998) 91:756-763.
24. NASH RA, ANTIN JH, KARANES C et al.: Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 96:2062-2068.
25. STORB R, DEEG HJ, FAREWELL V et al.: Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood (1986) 68:119-125.
26. MIELCAREK M, MARTIN PJ, LEISENRING W et al.: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 102:756-762.
27. KOTTARIDIS PD, MILLIGAN DW, CHOPRA R et al.: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96:2419-2425.
28. OR R, SHAPIRA MY, RESNICK I et al.: Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood (2003) 101:441-445.
29. CHILDS R, EPPERSON D, BAHCECI E, CLAVE E, BARRETT J: Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br. J. Haematol. (1999) 107:396-400.
30. MCSWEENEY PA, NIEDERWIESER D, SHIZURU JA et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 97:3390-3400.
31. WASSMANN B, SCHEURING U, THIEDE C et al.: Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. (2003) 31:611-614.
32. VANDENBERGHE P, BOECKX N, RONSYN E, DECORTE R, VERHOEF G, HAGEMEIJER A: Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. Leukemia (2003) 17:458-460.
33. MCCANN SR, GATELY K, CONNEALLY E, LAWLER M: Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML. Blood (2003) 101:1200-1201.
34. KANTARJIAN HM, O'BRIEN S, CORTES JE et al.: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2002) 100:1590-1595.
35. OLAVARRIA E, CRADDOCK C, DAZZI F et al.: Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood (2002) 99:3861-3862.
36. BURNETT AK: The role of BMT in addition to intensive chemotherapy in AML in first CR: Results MRC AML 10 trial. GASR. Blood (1994) 84:252 (abstract).
37. CASSILETH PA, HARRINGTON DP, APPELBAUM FR et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. (1998) 339:1649-1656.
38. HAROUSSEAU JL, CAHN JY, PIGNON B et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood (1997) 90:2978-2986.
39. FEINSTEIN LC, SANDMAIER BM, HEGENBART U et al.: Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br. J. Haematol. (2003) 120:281-288.
40. ANDERLINI P: Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status. Cytotherapy (2002) 4:241-251.
41. ROBINSON SP: Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression-free survival. MSGA. Blood (2000) 96:554 (abstract).
42. CARELLA AM, CAVALIERE M, LERMA E et al.: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J. Clin. Oncol. (2000) 18:3918-3924.
43. RATANATHARATHORN V, UBERTI J, KARANES C et al.: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood (1994) 84:1050-1055.
44. CHOPRA R, GOLDSTONE AH, PEARCE R et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J. Clin. Oncol. (1992) 10:1690-1695.
45. KHOURI IF, SALIBA RM, GIRALT SA et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood (2001) 98:3595-3599.
46. KHOURI IF: Long term remission and low mortality achieved with cisplatin, fludarabine, cytarabine nonablative preparative regimen and allogeneic stem cell transplantation (AST) for histologically aggressive non-Hodgkins lymphoma (NHL). SRGS. Blood (2001) 98:190a (abstract).
47. KHOURI IF, KEATING MJ, SALIBA RM, CHAMPLIN RE: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy (2002) 4:217-221.
48. DREGER P, BRAND R, HANSZ J et al.: Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia (2003) 17:841-848.
49. SCHETELIG J, THIEDE C, BORNHAUSER M et al.: Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Ann. Hematol. (2002) 81(Suppl. 2):S47-S48.
50. BELLUCCI R, RITZ J: Allogeneic stem cell transplantation for multiple myeloma. Rev. Clin. Exp. Hematol. (2002) 6:205-224.
51. BJORKSTRAND BB, LJUNGMAN P, SVENSSON H et al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood (1996) 88:4711-4718.
52. MALONEY DG, SANDMAIER BM, MACKINNON S, SHIZURU JA: Non-myeloablative transplantation. Hematology (Am. Soc. Hematol. Educ. Program.) (2002):392-421.
53. BEN YOSEF R, OR R, NAGLER A, SLAVIN S: Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet (1996) 348:1242-1243.
54. EIBL B, SCHWAIGHOFER H, NACHBAUR D et al.: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 88:1501-1508.
55. UENO NT, RONDON G, MIRZA NQ et al.: Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. (1998) 16:986-993.
56. CHILDS R, CHERNOFF A, CONTENTIN N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. (2000) 343:750-758.
57. MENA O, IGARASHI T: Immunologic mechanisms involved in the graft-vs-tumor (GVT) effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation (NST). American Society of Hematology Meeting, Philadelphia, USA (2001) (abstract).
58. CHILDS R, BRADSTOCK K: Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. American Society of Hematology Meeting, Philadelphia, USA (2002) (abstract).
59. GIRALT S, THALL PF, KHOURI I et al.: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood (2001) 97:631-637.
60. PEDRAZZOLI P, DA PRADA GA, GIORGIANI G et al.: Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer (2002) 94:2409-2415.
61. RINI BI, ZIMMERMAN T: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. (2002) 20(8):2017-2024.
62. BREGNI M, DODERO A, PECCATORI J et al.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood (2002) 99:4234-4236.
63. HENTSCHKE P, BARKHOLT L, UZUNEL M et al.: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. (2003) 31:253-261.
64. BAY JO, FLEURY J, CHOUFI B et al.: Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. (2002) 30:95-102.
65. BORNHAUSER M, HAENEL M, PLATZBECKER U: Graft-versus-tumor effects after reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation for ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2002):A2954 (abstract).
66. PEDRAZZOLI P: Allogeneic hematopoietic stem cell transplantation (alloHSCT) following reduced-intensity chemotherapy for sarcoma. GGSR. Proc. Am. Soc. Clin. Oncol. (2002):A2949 (abstract).
67. MAKIMOTO A, KAMI M, MINEISHI R: Reduced-intensity allogeneic stem-cell transplantation (RIST) for patients including children with refractory sarcomas. Proc. Am. Soc. Clin. Oncol. (2003):A3355 (abstract).
68. OMURO Y, MATSUMOTO G, SASAKI T et al.: Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Bone Marrow Transplant. (2003) 31:943-945.
69. KANDA Y, KOMATSU Y, AKAHANE M: Allogeneic reduced intensity stem cell transplantation for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2003):A3353 (abstract).